Controversies in prostate cancer screening.
暂无分享,去创建一个
[1] P. Humphrey,et al. The early detection of prostate carcinoma with prostate specific antigen , 1997, Cancer.
[2] J. Waye,et al. Colonoscopy: a prospective report of complications. , 1992, Journal of clinical gastroenterology.
[3] F. Schröder,et al. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC). , 2005, The Canadian journal of urology.
[4] J. Boone,et al. Determining Sensitivity of Mammography from Screening Data, Cancer Incidence, and Receiver-Operating Characteristic Curve Parameters , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.
[5] W. Catalona,et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.
[6] T. Wheeler,et al. Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. , 2004, The Journal of urology.
[7] H. D. de Koning,et al. European randomized study of screening for prostate cancer. Progress report of Antwerp and Rotterdam Pilot studies , 1995, Cancer.
[8] M. Naslund,et al. An economic rationale forprostate cancer screening , 1994 .
[9] T. To,et al. The Canadian National Breast Screening Study-1: Breast Cancer Mortality after 11 to 16 Years of Follow-up: A Randomized Screening Trial of Mammography in Women Age 40 to 49 Years , 2002, Annals of Internal Medicine.
[10] F. Labrie,et al. Screening decreases prostate cancer mortality: 11‐year follow‐up of the 1988 Quebec prospective randomized controlled trial , 2004, The Prostate.
[11] Alicia Samuels,et al. Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.
[12] M. Cowen,et al. A Markov model of the natural history of prostate cancer. , 1994, Journal of clinical epidemiology.
[13] A. Partin,et al. Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence. , 2002, Urology.
[14] E. Arias,et al. Deaths: preliminary data for 2011. , 2012, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[15] T. Tong,et al. Cancer statistics, 1993 , 1993, CA: a cancer journal for clinicians.
[16] P. Walsh,et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.
[17] M. Roobol,et al. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. , 2002, Urology.
[18] Juni Palmgren,et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. , 2002, The New England journal of medicine.
[19] Peter Boyle,et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. , 2001 .